Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Neuroendocrine Tumors
Study Phase
Phase 3
Study Completion Date
January 2015
NCT00569127Uploaded 02-24-2018
Access via NCI by Request
PDS UID: nci-data-371
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Files: NCT00569127-D2
Data DictionaryNCT00569127-D2-Data-Dictionary.pdf
DATANCT00569127-D2-Dataset.csv
OTHERREADME.pdf
Files: NCT00569127-D1
Data DictionaryNCT00569127-D1-Data-Dictionary.pdf
DATANCT00569127-D1-Dataset.csv
OTHERREADME.pdf